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Abstract
In recent years, advances in metabolic imaging have become dependable tools for the diagnosis and treatment
assessment in cancer. Dynamic nuclear polarization (DNP) has recently emerged as a promising technology in
hyperpolarized (HP) magnetic resonance imaging (MRI) and has reached clinical relevance with the successful
visualization of [1-13C] pyruvate as a molecular imaging probe in human prostate cancer. This review focuses on
introducing representative compounds relevant to metabolism that are characteristic of cancer tissue: aerobic
glycolysis and pyruvate metabolism, glutamine addiction and glutamine/glutamate metabolism, and the redox
state and ascorbate/dehydroascorbate metabolism. In addition, a brief introduction of probes that can be used to
trace necrosis, pH changes, and other pathways relevant to cancer is presented to demonstrate the potential that
HP MRI has to revolutionize the use of molecular imaging for diagnosis and assessment of treatments in cancer.
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Introduction
Since the hallmark discovery of the Warburg effect in
cancer cells in the 1920s, it has been widely accepted
that the metabolic properties of cancer cells are vastly
different from those of normal cells [1]. Starting from
the observation that many cancerous (neoplastic) cells
have higher rates of glucose utilization and lactate produc-
tion, the development of tools and methods to correlate
specific cellular metabolic processes to different types of
cancer cells has received increased research focus [2, 3].
Several imaging techniques are currently in use for
this purpose, including radiography, scintigraphy, positron
emission tomography (PET), single-photon emission
computed tomography (SPECT), and magnetic resonance
(MR) [4, 5].
For more than 30 years, MR has been a revolutionary
diagnostic tool, used in a wide range of settings from the
central nervous system to cardiomyopathies and cancers.
MR imaging (MRI) can outline molecular and cellular
processes with high spatial resolution. Typically, MRI
of body tissues is achieved via contrast visualization of
the protons (1H) of water, which are present in high
abundance in living systems. This can be extended to
MR spectroscopy (MRS), which can further differentiate
between less abundant, carbon-bearing, biological metabo-
lites in vivo utilizing 1Hs of these compounds [6, 7]. How-
ever, despite its usefulness in imaging whole body tissues,
1H MRS has low spectral resolution and poor sensitivity
for these less abundant metabolites. In addition, 13C MRS
is increasingly difficult, in comparison to 1H MRS, in that
both the gyromagnetic ratio (approximately 25 % of 1H)
and natural abundance (1.1 % of 1H) are significantly
lower, making the detection of carbon-bearing compounds
difficult [8, 9]. The low spectral resolution of 1H MRS
for metabolites can be addressed by using 13C-enriched
compounds, and with this direct 13C MRS, metabolic
processes can be traced, utilizing enriched tags on specific
carbons in a given metabolite [10]. While enrichment of
molecules in 13C can also moderately address the sensitivity
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limitation of MRS, recent work in hyperpolarization (HP)
provides a means of dramatically increasing sensitivity and
enhancing signals, well beyond that of the equilibrium state
obtained via MRS. [11, 12]. The focus of this review will be
the introduction of this approach in the setting of cancer
metabolism, delineating probes of interest, which have been
applied to study metabolic processes in vivo.
Obtaining a hyperpolarized probe
In MR, a desired target is placed in a magnetic field
where the nuclear spins of molecules are aligned with or
against the direction of the magnetic field. The nuclear
spins have thus different energies, and an MR signal is
detected upon relaxation of nuclear spins of higher energy.
At thermal equilibrium, the number of spins aligned with
the magnetic field nearly equals the number of spins
opposing the direction of the magnetic field. Thus, at
thermal equilibrium, spin polarization is in the order
of >0.0005 % resulting in a limited signal. Signal in-
creases on the order of 100,000-fold can be achieved
by hyperpolarizing the system via the redistribution of
the spin population levels found at equilibrium [10, 13].
There are several techniques that have been used to
achieve hyperpolarization of various nuclei: spin-exchange
optical pumping of 3He and 129Xe, parahydrogen-induced
polarization (PHIP), and dissolution dynamic nuclear
polarization (DNP) [11, 14, 15]. Both PHIP and DNP tech-
niques can polarize biologically relevant nuclei like 13C
and 15N, although there is a wider range of molecules that
can be targeted for hyperpolarization using dissolution
DNP [14, 16–18].
The goal of DNP is the transfer of polarization from
highly polarized unpaired electron spins to the nuclear
spins of a desired target compound. This is achieved by
applying an external magnetic field to a free-radical
agent in order to polarize electron spins, followed by
saturating the electron spin resonance via microwave
irradiation in order to obtain polarization transfer. The
free-radical agent is generally a stable organic compound
that is compatible with aqueous buffers, which are used as
solvent in order to obtain a homogeneous distribution of
the radical [13]. Nearly 100 % of the electrons on the free-
radical agent are polarized when the free-radical/solvent
mixture is subjected to high magnetic fields (≥3.3 T)
followed by rapid freezing to 1 K using liquid helium
in order to obtain a sample frozen to an amorphous
state, which is necessary for retention and transfer of
polarization [18]. For biological applications, after transfer
of electron spin polarization to the nuclei of interest has
occurred, the preparation must exist in solution, which
can be achieved utilizing a dissolution process in which
the solid sample is rapidly melted via injection of a hot
solvent, typically a biologically compatible buffer, into the
frozen sample [13]. The dissolution process results in a
liquid sample at room temperature, while still preserving
the enhanced polarization obtained by the microwave
irradiation of the frozen sample [8]. Additionally, the
use of chelating agents (e.g., EDTA) with the solvent to
eliminate trace metals and more recently the use of
gadolinium (Gd) chelates with the DNP sample have
been used to further enhance and retain polarization in
the liquid sample, albeit with caution over potential
toxic effects when applied in vivo and the potential for loss
of hyperpolarization due to T1 shortening [11, 19, 20].
More in-depth exploration of the technical aspects of
probe development has been previously reviewed [8, 11].
Considerations in probe selection and current research
The usefulness of a molecule for hyperpolarized MRS is
dependent on the polarization lifetime of the nucleus of
interest, and this property is determined by the spin-
lattice relaxation constant (T1) [21]. Dipolar coupling,
the magnetic field range, and molecular size can also
affect the T1 of a given nucleus. In general, high mag-
netic fields and large molecular weights decrease the T1.
Dipole-dipole coupling of 13C with 1H is common in
biologically relevant molecules, and it shortens relaxation
times; therefore, carbon atoms directly bound to 1H are
generally not useful as probes for HP. For example, all
carbons present in glucose (an important substrate in
cancer cells) have relaxation times shorter than 2 s [22].
On the other hand, carbonyl carbons of biologically rele-
vant molecules generally have T1’s above 20 s even at high
magnetic fields like [1-13C] pyruvic acid, which has relax-
ation times of 67, 48, and 44 s at 3, 11.7, and 14.1 T, re-
spectively [23–25]. Even carbons that are less oxidized
than carbonyls, like the hemi-ketal in [2-13C] fructose have
T1’s one order of magnitude higher than glucose carbons.
Short spin-lattice relaxation times can sometimes be in-
creased by deuterium enrichment of the sample. With this
technique, protons that are directly bound to carbons are
exchanged for deuterium atoms which results in the re-
duction of dipole-dipole relaxation, further preserving the
hyperpolarized state [26]. This has resulted in increased
T1’s of
13C nuclei in molecules such as glucose (T1 in-
creased from 2 s to 10–14 s), providing the possibility of
utilizing them in future metabolic studies [27–29]. Despite
the effect of deuterium enrichment, research efforts have
largely focused on developing carbonyl-bearing molecules
as molecular imaging probes. The focus of this review is
to introduce representative compounds relevant to metab-
olism that are characteristic of cancer tissue and have been
applied in the work of multiple groups: aerobic glycolysis,
glutamine addiction, and the redox state.
Pyruvate and aerobic glycolysis
Of particular interest to cancer metabolism is the in-
creased conversion of glucose to lactate as a result of
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modulated aerobic glycolysis. This process, also known
as the Warburg effect, is characteristic of many tumors
with altered metabolism where pyruvate generated from
glucose metabolism via glycolysis is preferentially converted
to lactate by lactate dehydrogenase (LDH) as opposed to
entering the tricarboxylic acid cycle [1]. With this pheno-
type, cancer cells show a preference for lactate fermentation
even in the presence of oxygen, thus bypassing oxidative
respiration for ATP generation. Because of this, pyruvate
has been the preferred probe for HP MRS research since it
is an intermediate metabolite in pathways characteristic of
aberrant metabolism in cancer cells, including increased
lactate production as a result of aerobic glycolysis where
detection of HP pyruvate-derived lactate can be used as
a marker for cancer and response to treatment [30, 31]
as well as an intermediate in amino acid metabolism
(e.g., interconversion to alanine via transamination with
glutamate) (Fig. 1). In addition, as mentioned before,
carbonyl carbons in pyruvate have long relaxation times
where even the methyl carbon can have T1’s above 50 s
after deuterium enrichment [32]. The interconversion
of pyruvate to lactate has been exploited for MRI by
using [1-13C] pyruvate and detecting the accumulation
of increased lactate in cancerous tissue as compared to
surrounding benign tissue. Increased conversion of
pyruvate to lactate and alanine has been demonstrated to
precede MYC-driven tumorigenesis by using HP [1-13C]
pyruvate in murine models [33]. Furthermore, in the same
study, a decrease in the flux of alanine was observed at the
tumor stage while a decrease in lactate conversion was
indicative of tumor regression [33]. In transgenic adeno-
carcinoma of mouse prostate (TRAMP) models, in vivo
studies using HP [1-13C] pyruvate demonstrated that
hyperpolarized pyruvate and its metabolic products can be
used non-invasively and with high specificity to obtain a
profile of the histologic grade of prostate cancers [34]. In
vivo imaging following hyperpolarized pyruvate has also
been used to evaluate the role of glutaminase and LDH
in human lymphoma models [35] as well as to elucidate
metabolism of pyruvate in breast cancer [36] and renal
cell carcinoma with treatment [30, 37].
Early work that utilized HP pyruvate to assess the re-
sponse of tumors to treatment was conducted in mice
xenografted with EL-4 lymphoma cells and treated with
etoposide, a topoisomerase inhibitor that causes rapid
cell death [38, 39]. In this study, tumor necrosis was cor-
related to a decrease in the flux of hyperpolarized lactate
which was suggested to be due to a decrease in NAD+
and NADH in the intracellular pool as well as loss of
LDH function. More recently, HP [1-13C] pyruvate has
been used as a biomarker to evaluate early response to
radiation therapy in glioma tumors by observing a de-
crease in hyperpolarized lactate suggested to be a result
of changes in tumor perfusion which can be detected
between 24 and 96 h following treatment [40, 41]. HP
[1-13C] pyruvate has also been used to detect early re-
sponse to temozolomide (TMZ) treatment on human
glioblastoma rat models [42]. The study successfully
showed for the first time detection of response to TMZ
therapy 1 day after TMZ administration. The continued
reports on using HP pyruvate as an imaging probe for
assessing treatment response indicate the potential of
the compound to become a standard in the field. More-
over, these studies demonstrate the usefulness of HP
[1-13C] pyruvate as a tool for early assessment of ther-
apy response, which can improve treatment selection at
the clinical level. Pyruvate has also been validated as a
metabolic imaging marker for use in humans [43]. In a
two-phase study, patients with biopsy-proven prostate
cancer of various histological grades were injected with
HP [1-13C] pyruvate. In the first phase, a maximum dose
level was determined to establish pharmacological safety
of the HP probe while still injecting enough pyruvate to
allow visualization. This addressed one of the major chal-
lenges faced in translating HP MRI to clinical applications:
the potential toxicity of compounds that must be injected
into patients. In the second phase, metabolism of pyruvate
was visualized in real time and differences in the ratio of
[1-13C] lactate to [1-13C] pyruvate between identified can-
cerous regions and normal tissue regions were successfully
observed (Fig. 1a–d). [1-13C] lactate in regions that did
not contain tumor was not detected, confirming previous
biopsy and preclinical studies that demonstrated low flux
of [1-13C] pyruvate to lactate and low concentrations of
lactate in benign prostate tissues [44, 45]. Preliminary re-
sults indicated the possibility of detecting previously unob-
served cancerous regions by HP [1-13C] pyruvate, later
confirmed to be Gleason 4+3 cancer by biopsy, though
further investigation into the relationship between grade
and metabolism in prostate cancer patients is needed.
While there are challenges associated with translation to
clinical use for HP [1-13C] pyruvate, the first in human
study demonstrated the feasibility of hyperpolarization
technology as a safe diagnostic tool and provides the
potential for utilizing this approach in preclinical models
with direct translation to the clinic.
Glutamine metabolism
Glutamine is an amino acid that plays an important
cellular role as nitrogen donor in the form of an amide
group for purine and pyrimidine biosynthesis, leaving a
glutamate molecule in the process although glutamine
can also be converted to glutamate by glutaminase in a
reaction independent of nucleotide biosynthesis. Glutamate
is the primary nitrogen donor for the biosynthesis of
non-essential amino acids. Transaminases catalyze the
transfer of the amine group from glutamate to α-ketoacids
to synthesize alanine, aspartate (precursor for asparagine),
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Fig. 1 (See legend on next page.)
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serine (precursor for glycine and cysteine), ornithine
(precursor for arginine), and proline which is derived from
the glutamate carbon backbone. Glutamine is considered
a non-essential amino acid as it can be recycled from glu-
tamate and ammonia in a reaction catalyzed by glutamine
synthetase; however, some cancer cells show increase con-
sumption of glutamine and are unable to grow in the
absence of exogenous glutamine [46, 47]. This metabolic
characteristic of cells to require exogenous glutamine for
growth has been termed “glutamine addiction” and has
generated extensive research interest as an indicator of de-
velopment of cancerous tissues [48]. In particular to the
field of HP MRI, the conversion rate of glutamine to glu-
tamate (Fig. 2) was explored in hepatocellular carcinoma
Fig. 2 Metabolism of [5-13C] glutamine to [5-13C] glutamate. a Time-dependent spectral data following conversion of [5-13C] glutamine to [5-13C]
glutamate. The signals are from 13C-enriched [5-13C]glutamate at 181.5 ppm and [5-13C]glutamine at 178.5 ppm and from natural abundance
13C label in [1-13C]glutamate at 175.2 ppm and [1-13C]glutamine at 174.7 ppm. b Plot of the ratio of the signal intensities of [5-13C]glutamate/
[5-13C]glutamine showing the ratio in hepatoma cells (shaded circle), cell lysate (square), and control (triangle). These results demonstrated that
hepatoma cancer cells convert glutamine to glutamine at a higher rate than normal cells. Adapted with permission from ref. [49]
(See figure on previous page.)
Fig. 1 Flux of hyperpolarized [1-13C] pyruvate to [1-13C] lactate in prostate regions. a MR image from patient with prostate cancer showing
regions of cancerous tissue and surrounding normal tissue. b–d Localized dynamic hyperpolarized [1-13C]pyruvate and [1-13C]lactate spectral from
voxels overlapping the contralateral region of prostate (turquoise), a region of prostate cancer (yellow), and a vessel outside the prostate (green).
Adapted with permission from ref. [43]
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(HCC) using a [5-13C] glutamine probe (Fig. 2) [49]. Using
the ratio between [5-13C] glutamine and [5-13C] glutam-
ate, it was demonstrated that HCC cells convert glutamine
at a higher rate than normal cells supporting the notion of
glutamine addiction. One important aspect of this study
was the choice of [5-13C] glutamine as a probe as opposed
to [1-13C] glutamine, which has a longer T1 (16.1 vs. 24.6 s
at 9.4 T) [49, 50]. [5-13C] glutamine was selected because
the chemical shift change obtained from [1-13C] in glu-
tamine and glutamate is far too small, which could prevent
proper identification and quantification of the peaks. This
highlights the importance of understanding not only
the target compound to be hyperpolarized but also the
metabolic products to be detected and their resulting
spectra in MR. This is further emphasized with studies
that demonstrate the usefulness of [1-13C] glutamine as
a source for [1-13C] glutamate in order to follow the
metabolism of α-ketoglutarate to observe the metabolic
state of the TCA cycle in transformed cells [51]. Further-
more, [1-13C] α-ketoglutarate has been hyperpolarized
and used to visualize other metabolic events involving
[1-13C] glutamate such as mutations in IDH1 expres-
sion in glioma tumors and pathways dependent on
hypoxia-inducible factor (HIF) [51–53]. More recently,
[5-13C] glutamine has been used to visualize the metab-
olism of liver cancer in vivo and in vitro, as well as the
treatment response of prostate cancer cells in vitro [54].
Based on the promise of glutamine as a biomarker for
cancer diagnosis and treatment response, extending the
spin-lattice relaxation time of the [5-13C] glutamine has
been researched and successfully accomplished. The facile
synthesis of [5-13C-4-2H2] glutamine has been reported,
and its study showed that by relying on the effect of deuter-
ium enrichment to lessen dipolar coupling effects, the T1 of
[5-13C] glutamine could be increased from approximately
15 to 30 s [55]. Visualization of real-time conversion of glu-
tamine to glutamate in SF188 cells was achieved using this
probe, demonstrating the promise of [5-13C-4-2H2] glutam-
ine as a probe for molecular imaging of metabolic events in
real time. Further investigation of this probe applied to in
vivo preclinical models will lay the foundation for its clin-
ical translational potential in the future.
Dehydroascorbate as a redox sensor
Reactive oxygen species (ROS) like the hydroxyl radical,
superoxide, and hydrogen peroxide have been shown to
cause DNA damage and can lead to mutations that
transform normal cells into cancerous cells [56]. The re-
duction/oxidation (redox) state, which is dependent on
the balance between oxidizing equivalents like ROS and
reducing cofactors, can provide insight into the physio-
logical condition of the cell with respect to potential can-
cer transformations. Furthermore, the presence of ROS in
tissue has been implicated to be a factor in developing
resistance to radiation therapies [57]. During oxidative
stress (i.e., when there is an increase in ROS), redox
homeostasis is maintained by the action of antioxidant
compounds, such as ascorbate (or vitamin C, VitC), which
can scavenge for ROS and reduce the compounds to rid
the cells of damaging agents [58]. In this process, ascor-
bate that is available to cells in high concentrations can be
oxidized to dehydroascorbate (DHA) while reducing ROS.
DHA can then be transported into the cell where DHA is
reduced back to ascorbate resulting in a process of recyc-
ling ascorbate and DHA (Fig. 3) [59]. In this sense, the
ratio of DHA to ascorbate can be used as a molecular
marker to investigate the redox state and thus the
physiological state of tissues. Additionally, conversion
of DHA to ascorbate can be enzymatically catalyzed in
an NADPH-dependent manner or via oxidation of gluta-
thione (GSH) to glutathione sulfide (GSSG); thus,
visualization of ascorbate/DHA metabolism offers a
method for probing in vivo metabolism of NADPH as well
as determination of GSSG to GSH ratio, both of which
have been implicated to be indicators of oxidative stress
in the cells, particularly for neurodegenerative, cardio-
vascular, and cancer diseases [60–62]. Hyperpolarized
[1-13C] DHA was successfully used in murine models
to detect increased reducing capacity in prostate can-
cer with the purpose of developing a non-invasive, early
diagnostic tool for improving selection of treatment ther-
apies [62, 63]. DHA demonstrates a relatively long T1 at
clinically relevant field strengths (>50 s at 3 T) and ad-
equate chemical shift separation between it and its meta-
bolic product ascorbate (δ = 3.8 ppm). Increased reduction
of HP [1-13C] DHA to ascorbate was observed in tumor
tissue compared to normal tissue as well as other meta-
bolic organs (Fig. 3). This was additionally demonstrated
in lymphoma cells, further supporting the potential for
using DHA as a probe in living systems [64]. A following
study validated these results, and the correlation between
increased DHA reduction and glutathione was established
in vivo, thus showing the utility of [1-13C] DHA as a mo-
lecular imaging probe to detect events that go beyond the
direct metabolism of DHA [63]. Notwithstanding the po-
tential of HP DHA as a diagnostic probe, the toxicity of
DHA remains to be validated. Earlier studies on mamma-
lian cells showed DHA toxicity starting at 10 mM, while a
study carried on rats demonstrated neurological effects of
DHA starting at injections of 50 mg/kg [65, 66]. However,
as outlined above, successful use of DHA injections in rats
and mice for hyperpolarization has been demonstrated
without reported side effects on the animals. More re-
search is needed to determine the parameters regarding
the toxicity of DHA in larger animal models using pure
formulations to assess its potential for clinical trials. Fur-
ther work in DHA could demonstrate its applicability for
the study of ROS and redox changes in model systems.
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Other metabolic imaging probes
While the three probes discussed earlier are the most
well studied in metabolic events that are characteristic
of cancer cells in general, other molecules have been
evaluated in their potential to be used as biomarkers.
Hyperpolarized bicarbonate (H13CO3
−) has been success-
fully used to determine the pH in extracellular matrix of
lymphoma tumors in mice, and a correlation between
acidic environments and cancer was established [67].
The relaxation times for bicarbonate compounds at 3 T
are between 34 and 50 s, which is enough time to detect
the rapid conversion of H13CO3
− and 13CO2 catalyzed by
carbonic anhydrase [23]. The attractive feature of this
probe is based on how ubiquitous acidic extracellular
environments are to a wide variety of diseases; thus, HP
bicarbonate has the potential for clinical translation beyond
cancer research, though extensive work will be necessary to
generate a preparation which will result in an adequate
dose for the clinic [68, 69]. More recently, the potential of
α-ketoisocaproate (KIC) as a molecular probe for in vivo
detection of branched chain amino acid transaminase
(BCAT) has been explored. BCAT catalyzes the conversion
of KIC to leucine, and its expression has been suggested to
correlate to genetic characterization of certain tumors. In a
pilot study, HP α-keto-[1-13C]-isocaproate was shown to
have a T1 of 100 s so its metabolism can be sensitively
traced for over a minute after injection [70]. In the same
study, metabolism of HP [1-13C] KIC to [1-13C] leucine by
BCAT was observed in murine lymphoma tumor tissue but
was absent in rat mammary adenocarcinoma with a correl-
ation between BCAT expression and [1-13C] leucine signal
detection [70]. Additionally, in the same models, [1-13C]
pyruvate conversion to [1-13C] lactate and [1-13C] alanine
was detected in both types of tumors. These findings show
the promise of using [1-13C] KIC as a discriminative probe
in addition to pyruvate in order to diagnose different types
of cancer [71, 72]. Furthermore, the correlation between
BCAT expression and [1-13C] leucine detection was also
shown in rat brain tissue, confirming the usefulness of HP
[1-13C] KIC in assessing BCAT activity in vivo [73]. Choline
is another compound that has been evaluated as a mo-
lecular imaging probe since elevated choline and choline-
derived metabolites have been correlated by 1H-MRS
imaging to cancer in the brain, breast, colon, cervix, and
prostate [74–76]. Despite its potential as a global marker
for cancer because of the long T1 relaxation times that can
be achieved with deuterium and 15N enrichment [77, 78],
HP applications of 13C enriched choline are limited due to
the small change in chemical shifts of choline and choline-
derived metabolites as well as its potential toxicity [16, 79,
80]. It has been shown that choline toxicity occurs at doses
of 53 mg/kg in mice, although a recent study successfully
detected HP 13C choline in vivo without adverse effects in
rats at doses of 50 mg/kg by using atropine to prevent cho-
linergic intoxication [81, 82] though metabolic products
have been difficult to visualize in vivo. As mentioned earlier,
the usefulness of glucose as a probe is limited due to
the short relaxation times of all the carbons present in the
molecule and although the T1’s can be increased through
deuterium enrichment, the lifetime of the probe remains a
hurdle for clinical applications [27, 28]. Thus, fructose
(a pentose analog of glucose) has been successfully used
as an alternative to probe glycolytic pathways [83] in
TRAMP models where differences in HP [2-13C] fructose
uptake and metabolism was visualized in tumor regions
compared to surrounding normal tissues. Like choline, the
limiting factor in the usefulness of [2-13C] fructose for
in vivo studies is in small chemical shifts between the
metabolite and its phosphorylated product. Finally, tumor
necrosis can be used as a measure of treatment response,
particularly early necrosis. HP [1,4-,13C] malate has been
Fig. 3 Determination of redox state by imaging of HP [1-13C]
ascorbate (VitC) and [1-13C] dehydroascorbate (DHA). Oxidative stress
caused by ROS (1.) can be alleviated by oxidation of ascorbate to
DHA (2.), and recycling of DHA to ascorbate can occur indirectly
with oxidation of glutathione (3.) or directly with oxidation of NADH
(4.). The ratio of [ascorbate] to [DHA] has been successfully used in
mice models as a biomarker to determine pH in vivo. Adapted with
permission from ref. [62]
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visualized in lymphoma mice models after injection of HP
[1,4-13C] fumarate [84]. In normal cells, fumarate has a
slow rate of transport into the mitochondria; however, in
necrotic cells where the mitochondrial membrane is
degraded, fumarase has access to the HP fumarate and
its ubiquitous cofactor, water, thus facilitating rapid
conversion to malate. Preliminary studies have shown
the potential for its use in animal models though further
work is required to determine the necessary density of
necrotic cells for detection and the timings required for
adequate visualization in patients.
Conclusions
The application of hyperpolarized 13C imaging has been
extensively investigated in preclinical models, and the
successful demonstration of HP [1-13C] pyruvate in pa-
tients with prostate cancer has validated the potential of
HP MRI as a safe diagnostic and treatment assessment
Fig. 4 Metabolic pathways with compounds that can be used as molecular imaging probes for HP MRI. A wide variety of metabolic pathways
have already been visualized or have the potential to be visualized using hyperpolarization technology that can be applied to different
pathological states of the cell including cardiovascular disease and a large variety of cancers. 1. Metabolism of C1 (red dots) in pyruvate. The
asterisks on selected compounds represent enrichment of 13C in the second pass of pyruvate in TCA cycle. 2. Metabolism of C1 (brown dots) in
DHA using a pool of NADPH derived from the pentose phosphate pathway. 3. Metabolism of C1 (blue dots) and C5 (green dots) of glutamine.
4. Metabolism of C1 and C4 (purple dots) of fumarate unrelated to TCA metabolites. 5. Metabolism of extracellular bicarbonate (gray dots). MTC1
monocarboxylate transporter 1, MTC4 monocarboxylate transporter 4, System ASC amino acid transporter, GLUTs glucose transporters, DCT
dicarboxylate transporter, DHAR dehydroascorbate reductase, GR glutathione reductase, GSH glutathione, GSSG glutathione disulfide, LDH lactate
dehydrogenase, ALT alanine transaminase, CA carbonic anhydrase, PC pyruvate carboxylase, PDH pyruvate dehydrogenase, CS citrate synthase,
GLS glutaminase, GLDH glutamate dehydrogenase, IDH isocitrate dehydrogenase, OGDC oxoglutarate dehydrogenase complex, SCS succinyl
CoA synthetase, SQR succinate dehydrogenase, FH fumarate hydratase, MDH malate dehydrogenase, FUM fumarase. Cofactors have been
omitted for brevity
Salamanca-Cardona and Keshari Cancer & Metabolism  (2015) 3:9 Page 8 of 11
tool. Application of other probes beyond pyruvate is still
in its infancy, particularly because of the need to further
study the currently developed models under conditions
that are relevant to a clinical setting (i.e., lower magnetic
fields) as well as to study the necessary parameters
(probe toxicity dose limits, safety limits for rapid injec-
tion) to withstand the necessary hurdles to translation.
Nevertheless, these vast research findings are promising
and indicate an eventual translation to humans. Further-
more, there is a large variety of biologically relevant
molecules that have the potential to be hyperpolarized
(Fig. 4), and molecular imaging of metabolic events in
real time using not only one single probe but a combin-
ation of relevant probes could become an invaluable tool
in elucidating so far undiscovered metabolic and prote-
omic interactions that play a role in cancer development
and treatment. This gives HP MRI the great potential to
revolutionize current molecular imaging technologies.
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